Stock market today: S&P 500 closes lower, but posts second weekly win
Immunovia publ AB (ST:IMMNOV) has announced final top-line data of the IMMray platform from a retrospective study in autoimmune diseases. The study showed that the IMMray biomarker platform could differentiate blood samples from patients with systemic lupus erythematosus (SLE) from other autoimmune diseases with 96% accuracy. This is an important first step to show the versatility and potential expansion of the IMMray technology to other indications. Immunovia’s main focus continues to be pancreatic cancer in high-risk individuals and newly diagnosed diabetic patients. Additionally, the company has reported full year 2016 financial results. Cash at end 2016 was SEK259m; we have updated our valuation to SEK151 per share.
IMMray shows potential in autoimmune diseases
Immunovia has reported the final top-line data from its IMMray biomarker microarray in autoimmune diseases. In particular, data from a retrospective trial in 315 blood samples designed to assess IMMray SLE biomarker signature showed that IMMray can differentiate samples with SLE from other diseases such as rheumatoid arthritis, vasculitis and Sjögren’s syndrome with 96% accuracy. The data are relevant as up to half of SLE cases are usually misdiagnosed, according to Immunovia. Furthermore, these data support further development of IMMray in autoimmune diseases, representing potential upside. We believe that Immunovia will now seek to conduct further validation studies, including in prospective trials.
To read the entire report Please click on the pdf File Below
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Which stock should you buy in your very next trade?
AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?
Unlock ProPicks AI